Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Sep
17
BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
Sep
17
BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
Sep
10
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care
Sep
10
Gen Z and Millennial Patients Find “Rheum for Improvement” in Disease Management
Sep
08
The profound impact on the lives of people living with thymidine kinase 2 deficiency (TK2d)
